Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103 Cell Injection in Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases
NCT07526493Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH103E in multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE) and 4 more, sponsored by Tongji Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Adverse Events at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
QH103E
03
Conditions
multiple sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)Autoimmune Encephalitis (AE)chronic inflammatory demyelinating polyneuropathy (CIDP)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07526493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526493.